Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/134490
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy |
Author: | D'Silva, A.M. Holland, S. Kariyawasam, D. Herbert, K. Barclay, P. Cairns, A. MacLennan, S.C. Ryan, M.M. Sampaio, H. Smith, N. Woodcock, I.R. Yiu, E.M. Alexander, I.E. Farrar, M.A. |
Citation: | Annals of Clinical and Translational Neurology, 2022; 9(3):339-350 |
Publisher: | Wiley |
Issue Date: | 2022 |
ISSN: | 2328-9503 2328-9503 |
Statement of Responsibility: | Arlene M. D’Silva, Sandra Holland, Didu Kariyawasam, Karen Herbert, Peter Barclay, Anita Cairns, Suzanna C. MacLennan, Monique M. Ryan, Hugo Sampaio, Nicholas Smith, Ian R. Woodcock, Eppie M. Yiu, Ian E. Alexander and Michelle A. Farrar |
Abstract: | Objective: To provide a greater understanding of the tolerability, safety and clinical outcomes of onasemnogene abeparvovec in real-world practice, in a broad population of infants with spinal muscular atrophy (SMA). Methods: A prospective cohort study of children with SMA treated with onasemnogene abeparvovec at Sydney Children's Hospital Network, Australia was conducted from August 2019 to November 2021. Safety outcomes included clinical and laboratory evaluations. Efficacy assessments included World Health Organisation (WHO) motor milestones, oral and swallowing abilities, and requirements for respiratory support. The implementation of a model of care for onasemnogene abeparvovec administration in health practice is described. Results: 21 children were treated (age range, 0.65–24 months; body weight range, 2.5–12.5 kg) and 19/21 (90.4%) had previous nusinersen. Transient treatment-related side effects occurred in all children; vomiting (100%), transaminitis (57%) and thrombocytopaenia (33%). Incidence of moderate/severe transaminitis was significantly greater in infants weighing ≥8 kg compared with <8 kg (p < 0.05). Duration of prednisolone following treatment was prolonged (mean 87.5 days, range 57–274 days). 16/21 (76%) children gained at least one WHO motor milestone. Stabilisation or improvement in bulbar or respiratory function was observed in 20/21 (95.2%) patients. Implementation challenges were mitigated by developing standard operating procedures and facilitating exchange of knowledge. Interpretation: This study provides real-world evidence to inform treatment decisions and guide therapeutic expectations for onasemnogene abeparvovec and combination therapy for SMA in health practice, especially for children weighing ≥8 kg receiving higher vector loads. Proactive clinical and laboratory surveillance is essential to facilitate individualised management of risks. |
Keywords: | Humans Muscular Atrophy, Spinal Spinal Muscular Atrophies of Childhood Prospective Studies Child Child, Preschool Infant Infant, Newborn Australia Genetic Therapy Drug-Related Side Effects and Adverse Reactions |
Description: | First published: 16 February 2022 |
Rights: | © 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
DOI: | 10.1002/acn3.51519 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/1194940 |
Published version: | http://dx.doi.org/10.1002/acn3.51519 |
Appears in Collections: | Medicine publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_134490.pdf | Published version | 547.96 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.